PT  - JOURNAL ARTICLE
AU  - John J O'Shea
AU  - Apostolos Kontzias
AU  - Kunihiro Yamaoka
AU  - Yoshiya Tanaka
AU  - Arian Laurence
TI  - Janus kinase inhibitors in autoimmune diseases
AID  - 10.1136/annrheumdis-2012-202576
DP  - 2013 Apr 01
TA  - Annals of the Rheumatic Diseases
PG  - ii111--ii115
VI  - 72
IP  - suppl 2
4099  - http://ard.bmj.com/content/72/suppl_2/ii111.short
4100  - http://ard.bmj.com/content/72/suppl_2/ii111.full
SO  - Ann Rheum Dis2013 Apr 01; 72
AB  - Biological therapies directed at proinflammatory cytokines have irrevocably changed the landscape of treatment of rheumatoid arthritis (RA) and other autoimmune diseases. With the advances in our knowledge in cytokine signalling, the question emerges whether targeting intracellular signalling might also be a safe and efficacious strategy. Janus kinases or Jaks are critical for a large family of cytokines and the first Jak inhibitors has been approved by the FDA. It is therefore timely to consider this new category of drugs and reflect on their potential roles, present and future, in the treatment of RA and related disorders.